PCN26 QUANTIFYING THE RELATIVE CLINICAL VALUE OF NIVOLUMAB PLUS IPILIMUMAB VS. SUNITINIB IN FIRST-LINE ADVANCED OR METASTATIC RENAL CELL CARCINOMA WITH THE NUMBER NEEDED TO TREAT AND NUMBER NEEDED TO HARM IN SPAIN AND PORTUGAL

Nov 1, 2019, 00:00 AM
10.1016/j.jval.2019.09.223
https://www.valueinhealthjournal.com/article/S1098-3015(19)32601-4/fulltext
Section Title :
Section Order : 10170
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32601-4&doi=10.1016/j.jval.2019.09.223
HEOR Topics :
Tags :
Regions :